High levels of modified ceramides are a defining feature of murine and human cancer cachexia

Background Cancer cachexia (CCx) is a multifactorial energy-wasting syndrome reducing the efficiency of anti-cancer therapies, quality of life, and survival of cancer patients. In the past years, most studies focused on the identification of tumour and host-derived proteins contributing to CCx. Howe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Morigny, Pauline (VerfasserIn) , Zuber, Julia (VerfasserIn) , Haid, Mark (VerfasserIn) , Kaltenecker, Doris (VerfasserIn) , Riols, Fabien (VerfasserIn) , Lima, Joanna D.C. (VerfasserIn) , Simoes, Estefania (VerfasserIn) , Otoch, José Pinhata (VerfasserIn) , Schmidt, Sören Fisker (VerfasserIn) , Herzig, Stephan (VerfasserIn) , Adamski, Jerzy (VerfasserIn) , Seelaender, Marilia (VerfasserIn) , Berriel Diaz, Mauricio (VerfasserIn) , Rohm, Maria (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 08 October 2020
In: Journal of cachexia, sarcopenia and muscle
Year: 2020, Jahrgang: 11, Heft: 6, Pages: 1459-1475
ISSN:2190-6009
DOI:10.1002/jcsm.12626
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1002/jcsm.12626
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/jcsm.12626
Volltext
Verfasserangaben:Pauline Morigny, Julia Zuber, Mark Haid, Doris Kaltenecker, Fabien Riols, Joanna D.C. Lima, Estefania Simoes, José Pinhata Otoch, Sören Fisker Schmidt, Stephan Herzig, Jerzy Adamski, Marilia Seelaender, Mauricio Berriel Diaz & Maria Rohm

MARC

LEADER 00000caa a2200000 c 4500
001 1916709052
003 DE-627
005 20250716230908.0
007 cr uuu---uuuuu
008 250207s2020 xx |||||o 00| ||eng c
024 7 |a 10.1002/jcsm.12626  |2 doi 
035 |a (DE-627)1916709052 
035 |a (DE-599)KXP1916709052 
035 |a (OCoLC)1528018911 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Morigny, Pauline  |e VerfasserIn  |0 (DE-588)1355638070  |0 (DE-627)1916708838  |4 aut 
245 1 0 |a High levels of modified ceramides are a defining feature of murine and human cancer cachexia  |c Pauline Morigny, Julia Zuber, Mark Haid, Doris Kaltenecker, Fabien Riols, Joanna D.C. Lima, Estefania Simoes, José Pinhata Otoch, Sören Fisker Schmidt, Stephan Herzig, Jerzy Adamski, Marilia Seelaender, Mauricio Berriel Diaz & Maria Rohm 
264 1 |c 08 October 2020 
300 |b Illustrationen 
300 |a 17 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 07.02.2025 
520 |a Background Cancer cachexia (CCx) is a multifactorial energy-wasting syndrome reducing the efficiency of anti-cancer therapies, quality of life, and survival of cancer patients. In the past years, most studies focused on the identification of tumour and host-derived proteins contributing to CCx. However, there is still a lack of studies addressing the changes in bioactive lipids. The aim of this study was to identify specific lipid species as a hallmark of CCx by performing a broad range lipid analysis of plasma from well-established CCx mouse models as well as cachectic and weight stable cancer patients. Methods Plasma from non-cachectic (PBS-injected mice, NC26 tumour-bearing mice), pre-cachectic and cachectic mice (C26 and LLC tumour-bearing mice, ApcMin/+ mutant mice), and plasma from weight stable and cachectic patients with gastrointestinal cancer, were analysed using the Lipidyzer™ platform. In total, 13 lipid classes and more than 1100 lipid species, including sphingolipids, neutral and polar glycerolipids, were covered by the analysis. Correlation analysis between specific lipid species and readouts of CCx were performed. Lipidomics data were confirmed by gene expression analysis of metabolic organs to analyse enzymes involved in sphingolipid synthesis and degradation. Results A decrease in several lysophosphatidylcholine (LPC) species and an increase in numerous sphingolipids including sphingomyelins (SMs), ceramides (CERs), hexosyl-ceramides (HCERs) and lactosyl-ceramides (LCERs), were mutual features of CCx in both mice and cancer patients. Notably, sphingolipid levels gradually increased during cachexia development. Key enzymes involved in ceramide synthesis were elevated in liver but not in adipose, muscle, or tumour tissues, suggesting that ceramide turnover in the liver is a major contributor to elevated sphingolipid levels in CCx. LPC(16:1), LPC(20:3), SM(16:0), SM(24:1), CER(16:0), CER(24:1), HCER(16:0), and HCER(24:1) were the most consistently affected lipid species between mice and humans and correlated negatively (LPCs) or positively (SMs, CERs and HCERs) with the severity of body weight loss. Conclusions High levels of sphingolipids, specifically ceramides and modified ceramides, are a defining feature of murine and human CCx and may contribute to tissue wasting and skeletal muscle atrophy through the inhibition of anabolic signals. The progressive increase in sphingolipids during cachexia development supports their potential as early biomarkers for CCx. 
650 4 |a Cancer cachexia 
650 4 |a Ceramides 
650 4 |a Lipidomics 
650 4 |a Signalling lipids 
650 4 |a Sphingolipids 
700 1 |a Zuber, Julia  |e VerfasserIn  |4 aut 
700 1 |a Haid, Mark  |e VerfasserIn  |4 aut 
700 1 |a Kaltenecker, Doris  |e VerfasserIn  |4 aut 
700 1 |a Riols, Fabien  |e VerfasserIn  |4 aut 
700 1 |a Lima, Joanna D.C.  |e VerfasserIn  |4 aut 
700 1 |a Simoes, Estefania  |e VerfasserIn  |4 aut 
700 1 |a Otoch, José Pinhata  |e VerfasserIn  |4 aut 
700 1 |a Schmidt, Sören Fisker  |e VerfasserIn  |4 aut 
700 1 |a Herzig, Stephan  |d 1969-  |e VerfasserIn  |0 (DE-588)12146623X  |0 (DE-627)705470857  |0 (DE-576)292725949  |4 aut 
700 1 |a Adamski, Jerzy  |e VerfasserIn  |4 aut 
700 1 |a Seelaender, Marilia  |e VerfasserIn  |4 aut 
700 1 |a Berriel Diaz, Mauricio  |e VerfasserIn  |4 aut 
700 1 |a Rohm, Maria  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Journal of cachexia, sarcopenia and muscle  |d Hoboken, NJ : Wiley, 2010  |g 11(2020), 6, Seite 1459-1475  |h Online-Ressource  |w (DE-627)642886121  |w (DE-600)2586864-0  |w (DE-576)335781330  |x 2190-6009  |7 nnas  |a High levels of modified ceramides are a defining feature of murine and human cancer cachexia 
773 1 8 |g volume:11  |g year:2020  |g number:6  |g month:10  |g pages:1459-1475  |g extent:17  |a High levels of modified ceramides are a defining feature of murine and human cancer cachexia 
856 4 0 |u https://doi.org/10.1002/jcsm.12626  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1002/jcsm.12626  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20250207 
993 |a Article 
994 |a 2020 
998 |g 12146623X  |a Herzig, Stephan  |m 12146623X:Herzig, Stephan  |d 50000  |e 50000PH12146623X  |k 0/50000/  |p 10 
999 |a KXP-PPN1916709052  |e 4662054036 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"role":"aut","family":"Morigny","display":"Morigny, Pauline","roleDisplay":"VerfasserIn","given":"Pauline"},{"display":"Zuber, Julia","given":"Julia","roleDisplay":"VerfasserIn","role":"aut","family":"Zuber"},{"family":"Haid","role":"aut","given":"Mark","roleDisplay":"VerfasserIn","display":"Haid, Mark"},{"given":"Doris","roleDisplay":"VerfasserIn","display":"Kaltenecker, Doris","family":"Kaltenecker","role":"aut"},{"family":"Riols","role":"aut","given":"Fabien","roleDisplay":"VerfasserIn","display":"Riols, Fabien"},{"roleDisplay":"VerfasserIn","given":"Joanna D.C.","display":"Lima, Joanna D.C.","family":"Lima","role":"aut"},{"given":"Estefania","roleDisplay":"VerfasserIn","display":"Simoes, Estefania","family":"Simoes","role":"aut"},{"display":"Otoch, José Pinhata","roleDisplay":"VerfasserIn","given":"José Pinhata","role":"aut","family":"Otoch"},{"family":"Schmidt","role":"aut","given":"Sören Fisker","roleDisplay":"VerfasserIn","display":"Schmidt, Sören Fisker"},{"family":"Herzig","role":"aut","given":"Stephan","roleDisplay":"VerfasserIn","display":"Herzig, Stephan"},{"role":"aut","family":"Adamski","display":"Adamski, Jerzy","roleDisplay":"VerfasserIn","given":"Jerzy"},{"family":"Seelaender","role":"aut","roleDisplay":"VerfasserIn","given":"Marilia","display":"Seelaender, Marilia"},{"role":"aut","family":"Berriel Diaz","display":"Berriel Diaz, Mauricio","roleDisplay":"VerfasserIn","given":"Mauricio"},{"display":"Rohm, Maria","roleDisplay":"VerfasserIn","given":"Maria","role":"aut","family":"Rohm"}],"recId":"1916709052","language":["eng"],"id":{"eki":["1916709052"],"doi":["10.1002/jcsm.12626"]},"origin":[{"dateIssuedDisp":"08 October 2020","dateIssuedKey":"2020"}],"note":["Gesehen am 07.02.2025"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"relHost":[{"id":{"issn":["2190-6009"],"eki":["642886121"],"zdb":["2586864-0"]},"disp":"High levels of modified ceramides are a defining feature of murine and human cancer cachexiaJournal of cachexia, sarcopenia and muscle","language":["eng"],"title":[{"title":"Journal of cachexia, sarcopenia and muscle","title_sort":"Journal of cachexia, sarcopenia and muscle"}],"part":{"issue":"6","pages":"1459-1475","volume":"11","year":"2020","extent":"17","text":"11(2020), 6, Seite 1459-1475"},"recId":"642886121","origin":[{"dateIssuedDisp":"2010-","publisher":"Wiley ; Springer-Medizin-Verl.","publisherPlace":"Hoboken, NJ ; Heidelberg","dateIssuedKey":"2010"}],"note":["Gesehen am 16.05.24"],"pubHistory":["1.2010 -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"physDesc":[{"extent":"Online-Ressource"}]}],"physDesc":[{"noteIll":"Illustrationen","extent":"17 S."}],"title":[{"title_sort":"High levels of modified ceramides are a defining feature of murine and human cancer cachexia","title":"High levels of modified ceramides are a defining feature of murine and human cancer cachexia"}],"name":{"displayForm":["Pauline Morigny, Julia Zuber, Mark Haid, Doris Kaltenecker, Fabien Riols, Joanna D.C. Lima, Estefania Simoes, José Pinhata Otoch, Sören Fisker Schmidt, Stephan Herzig, Jerzy Adamski, Marilia Seelaender, Mauricio Berriel Diaz & Maria Rohm"]}} 
SRT |a MORIGNYPAUHIGHLEVELS0820